Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04178213
Other study ID # GLRA-G012
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 26, 2020
Est. completion date June 2022

Study information

Verified date February 2022
Source Admedus Regen Pty Ltd.
Contact Factory CRO
Phone +31 30 229 2727
Email jurriaan.sombeek@avaniaclinical.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the safety and performance of the ADAPT 3D - ALR in adult patients requiring replacement of aortic valve. 15 patients in one site in Belgium will all be treated with ADAPT 3D - ALR.


Description:

The purpose of this study is to conduct the initial clinical investigation of single piece ADAPT treated 3D - ALR (Aortic Leaflet Repair) to collect evidence on the device's safety and performance. The study is anticipated to confirm successful clinical safety and clinical performance with significant improvements in clinical hemodynamic performance. The ADAPT® technology is used to process animal derived tissues to produce implantable tissue prosthetic devices that are compatible with the human body. This technology has been shown to produce reliable, biocompatible and versatile regenerative prosthetic devices capable of being used instead of synthetic products currently used in many soft tissue repair applications. 15 patients with aortic valve insufficiency or stenosis will be enrolled in this single arm single site study. Follow-up will continue through to 26 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date June 2022
Est. primary completion date June 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. Patient is older than 18 years of age and = 85 years. 2. The subject's aortic annular measurements are = 21 mm to < 27mm as confirmed on pre-op echo. 3. The subject is a candidate for Aortic Valve Replacement. 4. The subject has documented moderate or severe Aortic Stenosis and/or Aortic Insufficiency (defined as grade 2, 3 or 4). 5. The subject is willing and able to comply with specified follow-up requirements and evaluations, including transesophageal echocardiography (TEE) if there are inadequate images by transthoracic echocardiography (TTE) to assess the aortic valve. 6. Patient has signed the informed consent Exclusion Criteria: 1. All patients who require emergency surgery (within 24 hours of a presentation to an emergency department) for any reason. 2. Subject with a pre-existing valve prosthesis in the aortic position. 3. Patients requiring repair of other cardiac valves will be excluded. 4. Subject with active endocarditis. 5. Heavily calcified aortic roots or "porcelain aortas". 6. Leukopenia with a WBC (white Blood Cells) of less than 3000. 7. Acute anaemia with a haemoglobin less than 8 g/dL. 8. Platelet count less than 100,000 platelets/microliter, and if less than 150,000 platelets/microliter, platelet reduction of >10,000 platelets/microliter per day over two consecutive days (Note: Where a platelet count is less than 150,000 platelets/microliter but greater than 100,000 platelets/microliter, platelet count testing is to be conducted over 2 consecutive days. If platelets are reducing over those two consecutive days, the rate of reduction in platelets must be less than 10,000 platelets/microliter per day, otherwise the participant must be excluded). 9. History of a defined bleeding diathesis or coagulopathy or the subject refuses blood transfusions. 10. Active infection requiring antibiotic therapy (if temporary illness, subjects may enroll 2-4 weeks after discontinuation of antibiotics). 11. Subjects in whom transesophageal echocardiography (TEE) is contraindicated. 12. Low EF < 50 %. 13. Life expectancy < 1 year, or severe comorbidities, such as cancer, dialysis, or severe COPD. 14. The subject is an illicit drug user, alcohol abuser, prisoner, institutionalised, or is unable to give informed consent. 15. The subject is pregnant or lactating (non-pregnancy to be confirmed by pregnancy test for all child bearing potential females). 16. Recent (within 6 months) cerebrovascular accident (CVA) or a transient ischemic attack (TIA). 17. Myocardial Infarction (MI) within one month of trial inclusion. 18. Currently participating in, or have been recently exited from (within 30 days of enrollment in this study), or plan to be enrolled in another clinical

Study Design


Intervention

Device:
Implantation of ADAPT 3D ALR
The operation is performed through a median sternotomy and with the hemodynamic support of standard cardiopulmonary bypass (CBP). diseased leaflets are excised meticulously. Calcifications at the level of the annulus will be removed just like in any other aortic valve replacement procedure. The annulus will be sized and the appropriate 3D single piece valve will be chosen. The implant technique will consist out of one running suture line at the level of the annulus, followed by fixation of the 3 commissural parts against the aortic wall. Valve competence and function will be assessed visually, and by TEE immediately coming of bypass.

Locations

Country Name City State
Belgium University Hospital Leuven Leuven

Sponsors (2)

Lead Sponsor Collaborator
Admedus Regen Pty Ltd. Factory CRO for Medical Devices B.V.

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary mean pressure gradient (mmHg) across the valve (less than 20 mmHg) Hemodynamic Performance Assessment 6 months following implantation
Primary derived Effective Orifice Area (EOA) range > 0.9 cm2 (19mm valve) to > 1.6 cm2 (27mm valve) Hemodynamic Performance Assessment 6 months following implantation
Primary rate of thromboembolism The adverse events consistent with the Objective Performance Criteria (OPC), for flexible heart valves will be compared to those rates defined as acceptable levels in the standard. 6 months following implantation
Primary rate of valve thrombosis The adverse events consistent with the Objective Performance Criteria (OPC), for flexible heart valves will be compared to those rates defined as acceptable levels in the standard. 6 months following implantation
Primary rate of major paravalvular leak The adverse events consistent with the Objective Performance Criteria (OPC), for flexible heart valves will be compared to those rates defined as acceptable levels in the standard. 6 months following implantation
Primary rate of major hemorrhage The adverse events consistent with the Objective Performance Criteria (OPC), for flexible heart valves will be compared to those rates defined as acceptable levels in the standard. 6 months following implantation
Primary rate of endocarditis The adverse events consistent with the Objective Performance Criteria (OPC), for flexible heart valves will be compared to those rates defined as acceptable levels in the standard. 6 months following implantation
Secondary Rate of Atrial Fibrillation 6 months post procedure New/post-operative atrial fibrillation - confirmed on ECG after closure till 6 months 6 months post procedure
Secondary number of days in ICU Length of stay in the ICU post valve implantation defined as arrival time/date in hours and minutes to transfer to ward time/date in hours and minutes. 30 days post procedure
Secondary NYHA (New York Heart Association) class Improvement Assessment Clinically significant improvement (one grade) in the New York Heart Association (NYHA) functional classification. 4 classes of disease: min value Class IV (cardiac disease resulting in inability to carry on any physical activity without discomfort); max value Class I (cardiac disease but without resulting limitations of physical activity) 6 months post procedure
Secondary number of days in hospital post procedure Post procedure length of stay defined as the date and time in hours and minutes documented for arrival in the recovery unit to date and time in hours and minutes of discharge in hours and minutes. 30 days post procedure
Secondary hemoglobin assessment Hemolysis screen measured by blood test 6 months post procedure
Secondary Alanine transaminase (ALT) Hemolysis screen measured by blood test of liver enzyme 6 months post procedure
Secondary Aspartate transaminase (AST) Hemolysis screen measured by blood test of liver enzyme 6 months post procedure
Secondary Rate of all-caused death The rate will be compared to clinical outcomes for surgically implanted heart valves reported in the literature. 6 months following implantation
Secondary Rate of valve related death The rate will be compared to clinical outcomes for surgically implanted heart valves reported in the literature. 6 months following implantation
Secondary Rate of valve-related reoperation The rate will be compared to clinical outcomes for surgically implanted heart valves reported in the literature. 6 months following implantation
Secondary Rate of valve explant The rate will be compared to clinical outcomes for surgically implanted heart valves reported in the literature. 6 months following implantation
Secondary Rate of hemorrhage The rate will be compared to clinical outcomes for surgically implanted heart valves reported in the literature. 6 months following implantation
Secondary Rate of all-cause reoperation The rate will be compared to clinical outcomes for surgically implanted heart valves reported in the literature. 6 months following implantation
Secondary Rate of Device deficiency Device deficiency measured by echo 6 months following implantation
See also
  Status Clinical Trial Phase
Recruiting NCT04310046 - Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial N/A
Completed NCT03332745 - Mechanism of Decompensation Evaluation - Aortic Stenosis
Recruiting NCT06008080 - Post-Market Clinical Follow Up Study With Navitor Valve
Recruiting NCT06055751 - Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
Active, not recruiting NCT04815785 - Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis N/A
Terminated NCT02202434 - Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement N/A
Recruiting NCT03029026 - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Active, not recruiting NCT02903420 - A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan) N/A
Completed NCT02629328 - CardioCel Tri-leaflet Repair Study N/A
Completed NCT02306226 - Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
Completed NCT01676727 - ADVANCE Direct Aortic Study
Withdrawn NCT01648309 - Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation N/A
Completed NCT01422044 - Risk Prediction in Aortic Stenosis N/A
Withdrawn NCT00774657 - Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography N/A
Terminated NCT00535899 - Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS) N/A
Terminated NCT05070130 - OpSens PRIME CLASS
Completed NCT03314857 - China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population N/A
Completed NCT04157920 - Impact of Predilatation Between Self-expanding Valves N/A
Enrolling by invitation NCT06212050 - Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
Recruiting NCT05893082 - Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR N/A